News & Updates

New drug applications approved by US FDA as of 16-29 February 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with denosumab in people with osteoporosis confers a protective effect against the risk of developing diabetes, according to the results of a propensity score–matched cohort study from Taiwan.

Tablet 4 mg and 16 mg

Powder for Injection (vial) 40 mg

The use of hydroxychloroquine during pregnancy does not appear to reduce the risk of pre-eclampsia among women with systemic lupus erythematosus, as shown in a study.

Among Asian patients with systemic lupus erythematosus (SLE), those who are younger, male, from ethnic minority backgrounds, and have suboptimal disease control at time of vaccination are at increased risk of flares following mRNA COVID-19 vaccination.

Treatment with rituximab (RTX) in children with juvenile dermatomyositis (JDM) and antibodies to antimelanoma differentiation-associated gene 5 (anti-MDA5) results in clinical improvements in interstitial lung disease (ILD) as well as in cutaneous manifestation and musculoskeletal disease activity, according to a study.